Paratek Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Paratek Pharmaceuticals, Inc.
After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.
No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances.
The $300m upfront payment should provide considerable runway for the base-editing company, which also plans multiple IND filings and enrolling the first patient in its sickle cell study this year.
Despite no mega-deals (yet), the J.P. Morgan Healthcare Conference’s first day brings the usual flurry of deals, including a pair of tie-ups each for Bristol and Pfizer. BioNTech moves into cancer with Crescendo.
- Other Names / Subsidiaries
- Novacea, Inc.
- Transcept Pharmaceuticals, Inc.
- TransOral Pharmaceuticals, Inc.